Business Context and Reporting Period
This Form 6-K filing by Mereo Biopharma Group Plc, a clinical-stage UK-based biopharmaceutical company focused on rare diseases, covers the month of July 2019. The report, dated July 24, 2019, serves as a notification of Director and other Persons Discharging Managerial Responsibilities (PDMR) dealings in accordance with the EU Market Abuse Regulation.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a regulatory disclosure regarding equity incentive grants.
Key transaction metrics include:
- Instrument: Options to acquire American Depositary Shares (ADSs).
- Exercise Price: $3.00 per ADS.
- Market Price Reference: The closing price on July 22, 2019, was $2.30 per ADS, meaning the exercise price was set at a premium.
- Consideration: All awards were granted for nil consideration.
Material Changes and Equity Grants
On July 23, 2019, the Company granted incentive awards to PDMRs under two distinct plans. These grants represent a material change in the equity compensation structure for the listed individuals.
2019 Equity Incentive Plan (Employees)
Options were granted to executive management with a vesting schedule of one-quarter on the first anniversary, followed by equal monthly installments over the subsequent three years.
| Name | Position | ADS Options Granted |
|---|---|---|
| Denise Scots-Knight | Chief Executive Officer | 87,500 |
| Alastair MacKinnon | Chief Medical Officer | 27,500 |
| Richard Jones | Chief Financial Officer | 27,500 |
| Charles Sermon | General Counsel | 27,500 |
| Wills Hughes-Wilson | Head of Patient Access and Commercial Planning | 18,000 |
| John Richard | Head of Corporate Development | 27,500 |
2019 Non-Employee Equity Incentive Plan (Directors)
Options were granted to non-employee directors with a vesting schedule of equal monthly installments over one year.
| Name | Position | ADS Options Granted |
|---|---|---|
| Peter Fellner | Chairman | 5,500 |
| Anders Ekblom | Director | 5,500 |
| Peter Bains | Director | 5,500 |
| Kunal Kashyap | Director | 5,500 |
| Paul Blackburn | Director | 5,500 |
| Deepa Pakianathan | Director | 5,500 |
| Michael Wyzga | Director | 5,500 |
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, or management commentary regarding the company's business strategy. It does not disclose new risks or contingencies beyond the standard forfeiture clause, which states that unvested awards shall be forfeited upon cessation of service.
Investor Verification Checklist
- Verify the total number of ADS options granted (240,000 total) against the company's authorized share pool limits.
- Confirm the impact of the $3.00 exercise price (set above the $2.30 market price) on the intrinsic value of the awards.
- Review the specific vesting schedules to understand future dilution timelines (3-year vesting for executives vs. 1-year for directors).
- Check subsequent filings for any changes in PDMR status that might trigger forfeiture of these awards.